Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073216 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT00073216: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00073216 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 96 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073216, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also test the safety of and immune response to a protein vaccine given alone.
Interventions
- BIOLOGICAL Clade B gag DNA/PLG and env DNA/PLG Microparticles
- BIOLOGICAL Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
What the finished NCT00073216 record still lists
NCT00073216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher).
The record links to 0 conditions, and to 2 interventions - of which Clade B gag DNA/PLG and env DNA/PLG Microparticles is the first listed.
NCT00073216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00073216 about?
NCT00073216 is a clinical study titled "Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults". To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also ...
What is the current status of trial NCT00073216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00073216?
The interventions under investigation include: Clade B gag DNA/PLG and env DNA/PLG Microparticles (BIOLOGICAL), Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00073216?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00073216's enrollment target sits among peer trials
96 600th of 2000 higher than 1,391 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery